John R Falck Selected Research

Cytochrome P-450 Enzyme System (Cytochrome P450)

10/2021	EET Analog Treatment Improves Insulin Signaling in a Genetic Mouse Model of Insulin Resistance.
10/2021	EET Analog Treatment Improves Insulin Signaling in a Genetic Mouse Model of Insulin Resistance.
9/2021	Novel Synthetic Analogues of 19(S/R)-Hydroxyeicosatetraenoic Acid Exhibit Noncompetitive Inhibitory Effect on the Activity of Cytochrome P450 1A1 and 1B1.
1/2021	20-HETE interferes with insulin signaling and contributes to obesity-driven insulin resistance.
12/2019	Eicosanoids derived from cytochrome P450 pathway of arachidonic acid and inflammatory shock.
11/2019	Development of Robust 17(R),18(S)-Epoxyeicosatetraenoic Acid (17,18-EEQ) Analogues as Potential Clinical Antiarrhythmic Agents.
10/2019	A synthetic epoxyeicosatrienoic acid analogue prevents the initiation of ischemic acute kidney injury.
1/2019	20-HETE synthesis inhibition promotes cerebral protection after intracerebral hemorrhage without inhibiting angiogenesis.
10/2018	20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats.
1/2018	The Cytochrome P450 Slow Metabolizers CYP2C92 and CYP2C93 Directly Regulate Tumorigenesis via Reduced Epoxyeicosatrienoic Acid Production.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John R Falck Research Topics

Disease

53	Hypertension (High Blood Pressure) 01/2022 - 07/2004
24	Inflammation (Inflammations) 03/2021 - 10/2005
21	Ischemia 01/2022 - 10/2004
15	Neoplasms (Cancer) 09/2021 - 12/2004
15	Infarction (Infarctions) 11/2018 - 10/2004
14	Hypoxia (Hypoxemia) 01/2022 - 08/2002
14	Reperfusion Injury 07/2020 - 10/2004
12	Obesity 01/2021 - 03/2008
10	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 05/2005
10	Insulin Resistance 10/2021 - 12/2009
10	Myocardial Infarction 01/2019 - 10/2004
10	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018 - 01/2009
8	Hypotension (Low Blood Pressure) 01/2022 - 01/2012
8	Septic Shock (Toxic Shock Syndrome) 01/2022 - 01/2012
8	Fibrosis (Cirrhosis) 01/2019 - 01/2013
6	Proteinuria 01/2019 - 10/2009
5	Tachycardia (Tachyarrhythmias) 01/2022 - 04/2013
5	Heart Failure 09/2021 - 01/2015
5	Hyperemia 01/2017 - 08/2005
4	Cardiomegaly (Heart Hypertrophy) 09/2021 - 02/2010
4	Breast Neoplasms (Breast Cancer) 10/2017 - 05/2011
4	Stroke (Strokes) 05/2017 - 12/2007
4	Body Weight (Weight, Body) 01/2012 - 12/2006
3	Hyperglycemia 01/2021 - 06/2006
3	Albuminuria 01/2019 - 01/2014
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 09/2011
3	Carcinogenesis 01/2018 - 06/2007
3	Vascular Remodeling 05/2017 - 04/2006
3	Renovascular Hypertension (Goldblatt Syndrome) 01/2016 - 12/2009
3	Hypertrophy 03/2015 - 02/2010
3	Vascular Ring 05/2011 - 08/2004
3	Myocardial Ischemia (Ischemic Heart Diseases) 01/2008 - 10/2004
2	Chronic Renal Insufficiency 03/2021 - 10/2017
2	Cerebral Hemorrhage 01/2021 - 01/2019
2	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 12/2004
2	Cardiac Arrhythmias (Arrythmia) 11/2019 - 01/2013

Drug/Important Bio-Agent (IBA)

70	20-hydroxy-5,8,11,14-eicosatetraenoic acidIBA 01/2022 - 08/2002
61	AcidsIBA 10/2021 - 10/2004
44	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 10/2021 - 07/2004
22	Arachidonic Acid (Vitamin F)IBA 01/2021 - 07/2004
15	EicosanoidsIBA 01/2021 - 01/2007
12	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2005
12	EnzymesIBA 01/2022 - 04/2005
12	Epoxide HydrolasesIBA 01/2019 - 04/2005
12	Cytochrome P-450 CYP4A (Alkane 1 Monooxygenase)IBA 01/2019 - 07/2004
11	Angiotensin IIIBA 01/2022 - 02/2010
11	AndrogensIBA 01/2020 - 12/2004
11	14,15-epoxy-5,8,11-eicosatrienoic acidIBA 10/2019 - 10/2005
11	Mixed Function Oxygenases (Monooxygenases)IBA 11/2018 - 10/2004
10	Hydroxyeicosatetraenoic Acids (HETE)IBA 01/2020 - 04/2005
9	HET0016IBA 01/2019 - 02/2005
9	SodiumIBA 12/2017 - 06/2006
9	SaltsIBA 01/2016 - 06/2006
8	Vasoconstrictor AgentsIBA 12/2019 - 02/2004
7	LipopolysaccharidesIBA 01/2022 - 03/2009
7	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2022 - 03/2009
7	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2020 - 08/2002
6	Messenger RNA (mRNA)IBA 08/2021 - 12/2005
6	CytochromesIBA 01/2021 - 10/2004
6	cytochrome P-450 CYP2C subfamilyIBA 11/2018 - 06/2007
5	N-(20-hydroxyeicosa-5,14-dienoyl)glycineIBA 01/2022 - 04/2013
5	Pharmaceutical PreparationsIBA 03/2021 - 10/2012
5	CytokinesIBA 12/2019 - 01/2012
5	LipidsIBA 01/2019 - 01/2012
5	ReninIBA 10/2018 - 12/2009
5	Antihypertensive Agents (Antihypertensives)IBA 01/2018 - 01/2014
5	AngiotensinsIBA 10/2017 - 01/2010
5	N- methylsulfonyl- 6- (2- propargyloxyphenyl)hexanamideIBA 01/2014 - 12/2004
5	Vasodilator Agents (Vasodilators)IBA 07/2013 - 07/2005
5	11,12-epoxy-5,8,14-eicosatrienoic acidIBA 06/2010 - 12/2005
4	Insulin (Novolin)FDA Link 10/2021 - 11/2018
4	EET-BIBA 01/2019 - 11/2013
4	DDMSIBA 01/2016 - 10/2004
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016 - 09/2011
4	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2014 - 07/2005
4	ProstaglandinsIBA 07/2013 - 07/2005
4	Adenosine Triphosphate (ATP)IBA 03/2007 - 08/2002
3	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2022 - 05/2017
3	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 10/2017
3	LigandsIBA 01/2021 - 06/2007
3	Oxygen (Dioxygen)IBA 12/2019 - 12/2009
3	Nitric Oxide Synthase (NO Synthase)IBA 12/2019 - 08/2002
3	EndotoxinsIBA 12/2019 - 01/2012
3	Phenylephrine (Neo-Synephrine)FDA LinkGeneric 10/2019 - 08/2004
3	CreatinineIBA 01/2019 - 10/2009
3	Heme Oxygenase (Decyclizing) (Heme Oxygenase)IBA 08/2017 - 12/2008
3	Cytochrome P-450 CYP2J2 (CYP2J2)IBA 01/2017 - 10/2010
3	OxylipinsIBA 01/2017 - 01/2017
3	salicylhydroxamic acid (SHAM)IBA 01/2017 - 03/2010
3	AdiponectinIBA 01/2015 - 12/2008
3	formamidine (formamidinium)IBA 03/2009 - 11/2005
2	Therapeutic UsesIBA 03/2021 - 12/2010
2	Cisplatin (Platino)FDA LinkGeneric 03/2021 - 08/2013
2	NitrogenIBA 12/2019 - 01/2012
2	BradykininIBA 12/2019 - 12/2011
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2019 - 02/2008

Therapy/Procedure

5	Therapeutics 08/2021 - 03/2017
3	Surgical Instruments (Clip) 10/2015 - 12/2009
2	Controlled Hypotension 01/2022 - 01/2012
2	Lasers (Laser) 01/2022 - 05/2011